Ryan Specialty (RYAN)

NYSE Financials Insurance Brokers S&P MidCap 400
$47.73
-0.53 (-1.10%)
Close of Nov 06, 2026 · end-of-day data

RYAN 8-K filings in 2024

Every material Form 8-K Ryan Specialty filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2024216 on record in all
Latest filing in 2024Dec 09, 2024financing
High impact (4-5)0of 2 briefs
TonePositive1Neutral1
financing 1earnings 1
Dec 9, 4:11 PM ET

Ryan Specialty completes $600 million add-on of 5.875% secured notes due 2032

Neutral financing Written later 1.012.03

Ryan Specialty, LLC, an indirect subsidiary of Ryan Specialty Holdings, completed a private offering of $600.0 million in additional 5.875% senior secured notes due 2032, issued at 99.500% of principal. The company plans to use some proceeds to temporarily repay up to $400.0 million of revolver borrowings used to help fund its $450.0 million acquisition of Innovisk Capital Partners, and the rest for acquisitions and general corporate purposes.

  • $600.0 million of New 2032 Notes issued on December 9, 2024 at 99.500% of principal
  • Notes have the same terms as the $600.0 million Existing 2032 Notes issued September 19, 2024
  • Up to $400.0 million of proceeds may repay Revolving Credit Facility borrowings tied to the Innovisk acquisition closed November 4, 2024
  • Notes are secured on a first-lien basis and guaranteed by subsidiaries, not by Ryan Specialty Holdings
Read the filing on SEC.gov ↗
Oct 30, 4:06 PM ET

Ryan Specialty Q3 revenue rises 20.5% to $604.7 million; net income up 82.4%

Positive earnings Written later 2.028.01

Ryan Specialty reported third quarter 2024 results, with total revenue up 20.5% year-over-year to $604.7 million and net income of $28.6 million, or $0.09 per diluted share, compared with a net loss attributable to the company in the prior-year period. The company kept its full-year 2024 outlook for organic revenue growth and Adjusted EBITDAC margin, and its board declared a regular quarterly dividend of $0.11 per share.

  • Total revenue grew 20.5% to $604.7 million; organic revenue growth slowed to 11.8% from 15.0% a year earlier
  • Net income rose 82.4% to $28.6 million; Adjusted diluted EPS rose 28.1% to $0.41
  • Full-year 2024 guidance maintained: organic revenue growth of 13.0% to 14.0% and Adjusted EBITDAC margin of 32.0% to 32.5%
  • Quarterly dividend of $0.11 per share payable November 26, 2024, to holders of record as of November 12, 2024
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ryan Specialty filing is on SEC EDGAR ↗. 8-K briefs of other companies →